دورية أكاديمية
The PD-1/PD-L1 Axis in the Biology of MASLD.
| العنوان: | The PD-1/PD-L1 Axis in the Biology of MASLD. |
|---|---|
| المؤلفون: | Pipitone RM; Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Piazza delle Cliniche, 90127 Palermo, Italy., Lupo G; Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Piazza delle Cliniche, 90127 Palermo, Italy., Zito R; Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Piazza delle Cliniche, 90127 Palermo, Italy., Javed A; Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Piazza delle Cliniche, 90127 Palermo, Italy., Petta S; Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Piazza delle Cliniche, 90127 Palermo, Italy., Pennisi G; Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Piazza delle Cliniche, 90127 Palermo, Italy., Grimaudo S; Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Piazza delle Cliniche, 90127 Palermo, Italy. |
| المصدر: | International journal of molecular sciences [Int J Mol Sci] 2024 Mar 25; Vol. 25 (7). Date of Electronic Publication: 2024 Mar 25. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Basel, Switzerland : MDPI, [2000- |
| مواضيع طبية MeSH: | Carcinoma, Hepatocellular* , Diabetes Mellitus, Type 2* , Fatty Liver* , Liver Neoplasms*, Humans ; B7-H1 Antigen ; Programmed Cell Death 1 Receptor |
| مستخلص: | Metabolic Dysfunction-Associated Steatotic Liver (MASL), previously named nonalcoholic fatty liver (NAFL), is a multifactorial disease in which metabolic, genetic, and environmental risk factors play a predominant role. Obesity and type 2 diabetes act as triggers of the inflammatory response, which contributes to the progression of MASL to Metabolic Dysfunction-Associated Steatohepatitis and the development of hepatocellular carcinoma. In the liver, several parenchymal, nonparenchymal, and immune cells maintain immunological homeostasis, and different regulatory pathways balance the activation of the innate and adaptative immune system. PD-1/PD-L1 signaling acts, in the maintenance of the balance between the immune responses and the tissue immune homeostasis, promoting self-tolerance through the modulation of activated T cells. Recently, PD-1 has received much attention for its roles in inducing an exhausted T cells phenotype, promoting the tumor escape from immune responses. Indeed, in MASLD, the excessive fat accumulation dysregulates the immune system, increasing cytotoxic lymphocytes and decreasing their cytolytic activity. In this context, T cells exacerbate liver damage and promote tumor progression. The aim of this review is to illustrate the main pathogenetic mechanisms by which the immune system promotes the progression of MASLD and the transition to HCC, as well as to discuss the possible therapeutic applications of PD-1/PD-L1 target therapy to activate T cells and reinvigorate immune surveillance against cancer. |
| References: | Liver Int. 2015 Feb;35(2):562-8. (PMID: 24351080) Nat Rev Immunol. 2015 Mar;15(3):137-48. (PMID: 25656706) Front Immunol. 2019 Nov 14;10:2670. (PMID: 31798592) Virchows Arch. 2022 Sep;481(3):455-465. (PMID: 35503185) Cancers (Basel). 2021 Mar 19;13(6):. (PMID: 33808740) Front Immunol. 2021 May 03;12:671073. (PMID: 34012454) Cell. 2015 Sep 10;162(6):1229-41. (PMID: 26321679) Nat Immunol. 2002 Sep;3(9):822-9. (PMID: 12154359) Immunol Cell Biol. 2009 Jan;87(1):30-8. (PMID: 19048016) PLoS One. 2013;8(1):e53626. (PMID: 23341960) Alcohol. 2020 May;84:27-32. (PMID: 31494259) J Immunol. 2002 Sep 15;169(6):3447-58. (PMID: 12218168) Cell. 2018 Nov 15;175(5):1289-1306.e20. (PMID: 30454647) Nature. 2021 Apr;592(7854):444-449. (PMID: 33762736) Hepatology. 2023 Apr 1;77(4):1335-1347. (PMID: 36626630) J Hepatol. 2020 May;72(5):946-959. (PMID: 31899206) Immunity. 1995 Nov;3(5):541-7. (PMID: 7584144) Diabetol Metab Syndr. 2016 Jun 13;8:38. (PMID: 27303448) J Immunol. 1998 Sep 15;161(6):2762-71. (PMID: 9743334) Gastroenterology. 2006 Feb;130(2):435-52. (PMID: 16472598) Cell Mol Immunol. 2016 May;13(3):267-76. (PMID: 27063467) Gastroenterology. 2020 May;158(7):1899-1912. (PMID: 32061598) Oncotarget. 2017 Apr 19;8(31):51936-51945. (PMID: 28881701) Nat Commun. 2015 Mar 26;6:6692. (PMID: 25809635) Hepatology. 2021 Aug;74(2):704-722. (PMID: 33609303) PLoS One. 2016 Jun 27;11(6):e0158156. (PMID: 27347680) J Immunol. 2014 Jan 15;192(2):553-7. (PMID: 24337740) Immunol Rev. 2009 May;229(1):114-25. (PMID: 19426218) Lancet. 2019 Dec 14;394(10215):2184-2196. (PMID: 31813633) Trends Immunol. 2015 Feb;36(2):71-80. (PMID: 25601541) Front Endocrinol (Lausanne). 2021 Oct 28;12:760860. (PMID: 34777255) Nat Rev Gastroenterol Hepatol. 2019 Jul;16(7):411-428. (PMID: 31028350) Hepatology. 2015 Jul;62(1):279-91. (PMID: 25810240) Cell Metab. 2023 Nov 7;35(11):1852-1871. (PMID: 37939656) Int Immunol. 1996 May;8(5):765-72. (PMID: 8671665) Annu Rev Immunol. 2008;26:677-704. (PMID: 18173375) Dig Dis Sci. 2016 May;61(5):1294-303. (PMID: 26841783) Hepatology. 2023 Oct 1;78(4):1223-1239. (PMID: 37162151) Hepatology. 2016 Jul;64(1):73-84. (PMID: 26707365) Hepatology. 2020 Sep;72(3):892-905. (PMID: 31943293) Nat Rev Immunol. 2017 Apr;17(4):248-261. (PMID: 28287106) Cell Rep. 2018 Nov 20;25(8):2053-2060.e4. (PMID: 30463004) Int J Mol Sci. 2022 Feb 28;23(5):. (PMID: 35269846) Gut. 2023 Jan;72(1):141-152. (PMID: 34933916) Clin Immunol. 2014 Jul;153(1):145-52. (PMID: 24780173) Annu Rev Pathol. 2006;1:23-61. (PMID: 18039107) Mol Cell Biol. 2013 Aug;33(16):3091-8. (PMID: 23732914) Nat Rev Gastroenterol Hepatol. 2018 Jun;15(6):349-364. (PMID: 29740166) Semin Immunopathol. 2009 Sep;31(3):279-82. (PMID: 19603169) J Immunol. 2008 Nov 15;181(10):6738-46. (PMID: 18981091) PLoS One. 2011;6(9):e25478. (PMID: 21980475) J Immunother Cancer. 2018 May 16;6(1):39. (PMID: 29769148) Nat Immunol. 2013 Oct;14(10):996-1006. (PMID: 24048121) Hepatol Commun. 2020 Jan 14;4(4):478-492. (PMID: 32258944) Gastroenterology. 2020 May;158(7):1999-2014.e1. (PMID: 32044314) Dig Liver Dis. 2024 Apr;56(4):579-588. (PMID: 37758610) Gut. 2012 Sep;61(9):1323-9. (PMID: 22427237) Annu Rev Immunol. 2007;25:297-336. (PMID: 17150027) Immunity. 2018 Mar 20;48(3):434-452. (PMID: 29562194) Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4275-80. (PMID: 20160101) Discov Med. 2009 Aug;8(41):55-60. (PMID: 19788868) Front Endocrinol (Lausanne). 2022 Nov 15;13:1051076. (PMID: 36457551) J Clin Invest. 2019 Jun 17;129(7):2629-2639. (PMID: 31205028) Cancers (Basel). 2021 Feb 10;13(4):. (PMID: 33578800) J Clin Invest. 2015 May;125(5):2046-58. (PMID: 25866972) Liver Int. 2023 Aug;43(8):1761-1771. (PMID: 37088979) Acta Biochim Biophys Sin (Shanghai). 2013 Sep;45(9):726-33. (PMID: 23786840) Nat Rev Immunol. 2012 Nov;12(11):749-61. (PMID: 23080391) Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):7355-9. (PMID: 8041794) J Immunol. 2016 Jan 1;196(1):97-105. (PMID: 26621860) Mol Aspects Med. 2019 Feb;65:37-55. (PMID: 30213667) Free Radic Biol Med. 2018 Aug 20;124:249-259. (PMID: 29920340) Int J Hepatol. 2012;2012:850836. (PMID: 22577564) Annu Rev Immunol. 2001;19:565-94. (PMID: 11244047) Animals (Basel). 2022 Oct 04;12(19):. (PMID: 36230402) Hepatology. 2014 Mar;59(3):886-97. (PMID: 24115128) Compr Physiol. 2013 Apr;3(2):567-98. (PMID: 23720323) Am J Physiol Gastrointest Liver Physiol. 2020 Feb 1;318(2):G211-G224. (PMID: 31709830) Nat Rev Immunol. 2002 Feb;2(2):116-26. (PMID: 11910893) Cell Mol Gastroenterol Hepatol. 2018 Jan 08;5(3):399-413. (PMID: 29552626) Nat Rev Immunol. 2022 Jul;22(7):429-443. (PMID: 34741169) Gastroenterol Clin North Am. 2020 Mar;49(1):141-149. (PMID: 32033760) Neurotherapeutics. 2014 Jul;11(3):636-50. (PMID: 24853068) Food Chem Toxicol. 2020 Sep;143:111556. (PMID: 32640349) J Clin Invest. 2016 Dec 1;126(12):4626-4639. (PMID: 27820698) Nat Immunol. 2020 Sep;21(9):1022-1033. (PMID: 32661364) Nature. 2021 Apr;592(7854):450-456. (PMID: 33762733) Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):E761-E770. (PMID: 28096382) Hepatol Commun. 2022 May;6(5):1032-1044. (PMID: 35146945) Nat Immunol. 2018 Jul;19(7):723-732. (PMID: 29915296) Immunity. 2019 Jul 16;51(1):77-89.e6. (PMID: 31229354) Nat Med. 2017 Mar 7;23(3):279-287. (PMID: 28267716) Cell Mol Immunol. 2016 May;13(3):354-68. (PMID: 26996069) J Biol Chem. 2012 Feb 24;287(9):6240-9. (PMID: 22223650) Nat Immunol. 2002 Jul;3(7):611-8. (PMID: 12087419) Aliment Pharmacol Ther. 2022 Mar;55(5):604-615. (PMID: 34988994) J Diabetes Res. 2019 Mar 17;2019:5035261. (PMID: 31008114) Cancers (Basel). 2019 Aug 10;11(8):. (PMID: 31405171) Cell Mol Immunol. 2021 Jan;18(1):45-56. (PMID: 33041338) Nature. 2017 Feb 8;542(7640):177-185. (PMID: 28179656) Int Immunol. 2004 Apr;16(4):533-8. (PMID: 15039383) Immunol Rev. 2010 Jul;236:219-42. (PMID: 20636820) Acta Pharmacol Sin. 2021 Jan;42(1):1-9. (PMID: 32152439) J Exp Med. 2016 Feb 8;213(2):167-76. (PMID: 26755705) Alcohol Clin Exp Res. 2007 Jan;31(1 Suppl):S83-7. (PMID: 17331172) Trends Immunol. 2010 Jun;31(6):220-7. (PMID: 20538542) Clin Exp Immunol. 2018 Sep;193(3):275-283. (PMID: 29920654) Hepatology. 2006 Feb;43(2 Suppl 1):S54-62. (PMID: 16447271) Annu Rev Immunol. 2009;27:147-63. (PMID: 19302037) Am J Physiol Gastrointest Liver Physiol. 2013 Dec;305(12):G891-9. (PMID: 24136786) Clin Exp Immunol. 2015 Jun;180(3):452-7. (PMID: 25682896) Analyst. 2016 Aug 2;141(16):4933-40. (PMID: 27301350) N Engl J Med. 2021 Oct 21;385(17):1547-1558. (PMID: 34670042) Am J Physiol Gastrointest Liver Physiol. 2015 Aug 15;309(4):G270-8. (PMID: 26113297) Hepatol Int. 2013 Jun;7(2):539-47. (PMID: 26201785) Annu Rev Physiol. 2016;78:181-205. (PMID: 26667070) Nat Med. 2009 Aug;15(8):921-9. (PMID: 19633657) Front Cell Dev Biol. 2023 May 16;11:1199519. (PMID: 37261074) Sci Transl Med. 2022 Mar 9;14(635):eabj6879. (PMID: 35263149) J Immunol. 2011 Feb 1;186(3):1338-42. (PMID: 21199897) Hepatology. 2014 Oct;60(4):1196-210. (PMID: 24845056) Gastroenterology. 2016 May;150(5):1147-1159.e5. (PMID: 26874076) Hepatol Commun. 2017 Jun;1(4):299-310. (PMID: 29152605) Sci Immunol. 2017 Apr 21;2(10):. (PMID: 28567448) Hepatology. 2018 Apr;67(4):1204-1206. (PMID: 29091293) Front Immunol. 2019 Jul 17;10:1587. (PMID: 31379820) Front Pharmacol. 2019 Mar 13;10:244. (PMID: 30949049) Front Immunol. 2022 Aug 10;13:967410. (PMID: 36032141) Nat Rev Gastroenterol Hepatol. 2020 Feb;17(2):81-92. (PMID: 31605031) Hepatology. 2018 Apr;67(4):1270-1283. (PMID: 28940700) Nat Immunol. 2010 Aug;11(8):674-80. (PMID: 20644573) Int J Environ Res Public Health. 2019 Nov 07;16(22):. (PMID: 31703268) J Exp Med. 2000 Jul 17;192(2):303-10. (PMID: 10899917) Nat Rev Immunol. 2018 Mar;18(3):153-167. (PMID: 28990585) Nat Rev Gastroenterol Hepatol. 2016 Feb;13(2):88-110. (PMID: 26758786) Cells. 2021 Oct 03;10(10):. (PMID: 34685625) Lancet. 2015 Mar 14;385(9972):956-65. (PMID: 25468160) Nat Rev Immunol. 2017 May;17(5):306-321. (PMID: 28317925) J Immunother Cancer. 2020 Sep;8(2):. (PMID: 32900861) J Hepatol. 2014 Nov;61(5):1106-14. (PMID: 24882050) |
| فهرسة مساهمة: | Keywords: CD8+ T cells exhausted; HCC; MASH; MASLD; PD-1; PD-L1; T Reg cells; cytotoxic lymphocytes |
| تواريخ الأحداث: | Date Created: 20240413 Date Completed: 20240415 Latest Revision: 20240521 |
| رمز التحديث: | 20240521 |
| مُعرف محوري في PubMed: | PMC11011676 |
| DOI: | 10.3390/ijms25073671 |
| PMID: | 38612483 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1422-0067 |
|---|---|
| DOI: | 10.3390/ijms25073671 |